Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
Leiter LA, Teoh H, Mosenzon O, Cahn A, Hirshberg B, Stahre CA, Hoekstra JB, Alvarsson M, Im K, Scirica BM, Bhatt DL, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Leiter LA, et al. Among authors: bhatt dl. Diabetes Obes Metab. 2016 Feb;18(2):186-90. doi: 10.1111/dom.12582. Epub 2015 Nov 27. Diabetes Obes Metab. 2016. PMID: 26443993 Clinical Trial.
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, Davidson J, Ohman P, Price DL, Frederich B, Udell JA, Braunwald E, Bhatt DL. Mosenzon O, et al. Among authors: bhatt dl. Diabetes Metab Res Rev. 2013 Jul;29(5):417-26. doi: 10.1002/dmrr.2413. Epub 2013 May 21. Diabetes Metab Res Rev. 2013. PMID: 23564755 Clinical Trial.
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators. Scirica BM, et al. Among authors: bhatt dl. Circulation. 2015 Oct 13;132(15):e198. doi: 10.1161/CIR.0000000000000330. Circulation. 2015. PMID: 26459088 No abstract available.
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
Gaba P, Bhatt DL, Dagenais GR, Bosch J, Maggioni AP, Widimsky P, Leong D, Fox KAA, Yusuf S, Eikelboom JW; COMPASS Steering Committee and Investigators. Gaba P, et al. Among authors: bhatt dl. JAMA Netw Open. 2022 Nov 1;5(11):e2243201. doi: 10.1001/jamanetworkopen.2022.43201. JAMA Netw Open. 2022. PMID: 36409491 Free PMC article. Clinical Trial.
Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
Winkel TA, Hoeks SE, Schouten O, Zeymer U, Limbourg T, Baumgartner I, Bhatt DL, Steg PG, Goto S, Röther J, Cacoub PP, Verhagen HJ, Bax JJ, Poldermans D. Winkel TA, et al. Among authors: bhatt dl. Eur J Vasc Endovasc Surg. 2010 Jul;40(1):9-16. doi: 10.1016/j.ejvs.2010.03.003. Epub 2010 Apr 10. Eur J Vasc Endovasc Surg. 2010. PMID: 20385507 Free article.
Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH.
Klooster CCV', Bhatt DL, Steg PG, Massaro JM, Dorresteijn JAN, Westerink J, Ruigrok YM, de Borst GJ, Asselbergs FW, van der Graaf Y, Visseren FLJ; UCC-SMART study group. Klooster CCV', et al. Among authors: bhatt dl. Int J Cardiol. 2021 Feb 15;325:140-148. doi: 10.1016/j.ijcard.2020.09.053. Epub 2020 Sep 25. Int J Cardiol. 2021. PMID: 32987048 Free article.
2,194 results